TYRA Latest Headlines

Dabogratinib’s Differentiated FGFR3 Profile and SURF302 Readout Position Tyra for Upside in Intermediate-Risk NMIBC

at www.tipranks.com (Mon, 20-Apr 8:15 AM)

Tyra Bioscience Expands Board, Appoints New Independent Director

at www.tipranks.com (Fri, 17-Apr 8:29 AM)

Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch

at www.tipranks.com (Thu, 16-Apr 12:33 PM)

Canaccord Genuity Sticks to Their Buy Rating for Tyra Bioscience (TYRA)

at www.tipranks.com (Thu, 16-Apr 7:27 AM)

This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

at www.benzinga.com (Wed, 15-Apr 9:10 AM)